Natera Inc. specializes in DNA blood tests that assist in early detection of health issues, including cancer and pregnancy complications. The stock has been navigating a long trading range, with recent momentum indicating a possible breakout. Analysts note a pattern of higher lows and higher highs, suggesting that NTRA could be poised for a significant upward movement.
If the stock breaks out, the target price could reach approximately 263, with a stop loss set at 203. Over the past three years, NTRA has generally been in an uptrend, with notable rallies following tests of its uptrend line. The latest test occurred recently, indicating the potential for another multi-month advance.
Additionally, NTRA has outperformed the XLV Healthcare ETF since late 2022, consistently breaking out of consolidation patterns, which bodes well for future performance. Continued relative strength could lead the stock back to previous highs and potentially beyond, making it an attractive option for investors looking for growth in the medical diagnostics sector